Clovis Oncology announces first patient enrolled in cancer trial
BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced the randomization of the first patient in the Phase 3 ATHENA trial evaluating the combination of Clovis Rubraca (rucaparib), a... Read More
Wednesday August 8, 2018 0 comments
Clovis Oncology receives European validation for Rubraca cancer drug
BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the European Medicines Agency (EMA) has validated the application for a Type II variation to the marketing authorization for Rubraca ... Read More
Thursday July 5, 2018 0 comments
Clovis Oncology announces European authorization of rucaparib for ovarian cancer care
BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced the European Commission (EC) has authorized Rubraca (rucaparib) as monotherapy treatment of adult patients with... Read More
Tuesday May 29, 2018 0 comments
Clovis Oncology announces FDA approval of Rubraca for ovarian cancer treatment
BOULDER -- Clovis Oncology, Inc. (NASDAQ:CLVS) announced the U.S. Food and Drug Administration (FDA) approved Rubraca (rucaparib) tablets for the maintenance treatment of adult patients with... Read More
Monday April 9, 2018 0 comments
Clovis Oncology’s Rubraca cancer treatment gets green light from EU
BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the European Unions (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive... Read More
Monday March 26, 2018 0 comments
Clovis: EU Medicines Agency approval sought for rucaparib cancer drug
BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced the European Unions (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has requested that... Read More
Tuesday December 19, 2017 0 comments
Clovis announces FDA priority review for rucaparib cancer drug
BOULDER -- Clovis Oncology (NASDAQ: CLVS) announced theU.S. Food and Drug Administration(FDA) has accepted the companys supplemental New Drug Application (sNDA) for rucaparib and... Read More
Wednesday December 6, 2017 0 comments
Clovis announces FDA application for accelerated approval of cancer drug
BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the U.S. Food and Drug Administration (FDA) has accepted Clovis New Drug Application (NDA) for accelerated approval of rucaparib and... Read More
Thursday August 25, 2016 0 comments
- 1
- 2
IN Sponsors
Browse
.jpg)
Entrepreneurial by Nature
